CD4+CD25+ Regulatory T-Cell Frequency in HER-2/neu (HER)-Positive and HER-Negative Advanced-Stage Breast Cancer Patients
Sonia A. Perez, Michael V. Karamouzis, Dimosthenes V. Skarlos, Alexandros Ardavanis, Nectaria N. Sotiriadou, Eleni G. Iliopoulou, Maria L. Salagianni, George Orphanos,Constantin N. Baxevanis, Gerasimos Rigatos, Michael Papamichail
Purpose: CD4+CD25bright regulatory T cells (Tregs) are increased in patients with several malignancies and correlate with disease stage and prognosis. Breast cancer patients represent a heterogeneous population with unpredictable disease progression even at advanced stages. Circulating Tregs in correlation with HER-2/neu (HER) status and treatment with chemotherapy, either alone or in combination with trastuzumab therapy, were monitored in advanced-stage breast cancer patients.
Experimental Design: Circulating Treg frequency and absolute counts of 46 HER+ and 28 HER−, stage III and IV, breast cancer patients before therapy and during trastuzumab therapy and/or chemotherapy have been compared with 24 healthy donors and correlated with plasma HER extracellular domain concentration and clinical outcome.
Increased Frequency of CD4+ Cells Expressing CD161 in Cancer Patients
Eleni G. Iliopoulou, Michalis V. Karamouzis, Ioannis Missitzis, Alexandros Ardavanis, Nectaria N. Sotiriadou, Constantin N. Baxevanis, Gerasimos Rigatos, Michael Papamichail,Sonia A. Perez
Purpose: Although the function of natural killer receptors on T cells infiltrating tumors and their potential effect on antitumor immunity has been investigated, little is known about T cells expressing NKR-P1A (CD161) in cancer patients. In the present study, we examined T cells expressing CD161 in the peripheral blood, the tumor tissue and in malignant effusions of patients with several types of malignancies.
Experimental Design: Expression of CD161 in CD4+ or CD8+ (lacking CD56) T cells isolated from peripheral blood (n = 61), tumor specimens (n = 8), and malignant effusions (n = 37) of cancer patients was examined using four-color flow cytometry.
- 1
- 2
Το Ινστιντούτο
Newsletter
Επικοινωνία
Email: info@imibe.org